ArticleAnnals of internal medicine2019

In high-risk patients with cancer, thromboprophylaxis with rivaroxaban did not reduce VTE events at 180 days.

Andrea Cervi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.